What limits the immersion treatment window in sea bream hatcheries when pH exceeds 8.2?

In shallow earthen ponds used for grow-out of gilt-head sea bream (Sparus aurata) and European sea bass (Dicentrarchus labrax), purified metrifonate is applied as a bath treatment against monogenean trematodes (Sparicotyle chrysophrii, Microcotyle mugilis) and parasitic copepods (Caligus minimus, Ergasilus sieboldi). The commercial API—supplied as a white crystalline powder with a minimum assay of 97.0% trichlorfon by anhydrous UV spectrophotometric determination per Pharmacopoeia Europaea monograph—is first diluted to a concentrated stock solution of 5–10% w/v in buffered deionized water at pH 5.5–6.0. The phosphate buffer system (0.05 M sodium dihydrogen phosphate adjusted with dilute sodium hydroxide) suppresses premature hydrolytic conversion to dichlorvos (DDVP), the actual acetylcholinesterase-inhibiting species responsible for therapeutic effect. Published first-order degradation data indicate that trichlorfon half-life in aqueous solution at 25°C ranges from 40–55 hours at pH 5.5, to 18–30 hours at pH 7.0, and contracts below 10 hours at pH 8.2. At pond water temperatures of 28–32°C during Mediterranean summer months, the half-life at pH 8.2 shortens further to 4–8 hours, which confines effective bath exposure to the early morning period when photosynthetic CO₂ uptake by microalgae has not yet driven pH above 8.0. This kinetic constraint is the primary determinant of application protocol design in marine finfish aquaculture.

Pond water pH	Water temperature (°C)	Published first-order hydrolysis half-life (hours)
5.5	15	70–95
5.5	25	40–55
7.0	15	35–48
7.0	25	18–30
8.2	15	12–18
8.2	25	< 10
8.2	30	4–8

The bath concentration applied in sea bream and sea bass production ranges from 0.25–0.5 ppm (mg/L) as trichlorfon active ingredient, with the lower threshold of 0.25 ppm reserved for fish below 50 g body weight due to the narrow therapeutic index of organophosphate acetylcholinesterase inhibitors in small fish. In high-density raceways and recirculating aquaculture systems, the treatment is prepared by injecting the 5–10% w/v stock solution through a Venturi eductor or peristaltic dosing pump (rated 2–20 L/h) into the inflowing water stream to achieve uniform distribution within 15–20 minutes. Pond aeration via paddlewheels or diffused air is maintained throughout the 1–2 hour immersion period to prevent hypoxic stress during treatment. Water samples are collected at three depths—surface, mid-water, and 0.2 m above sediment—at 30-minute intervals and analysed by LC-MS/MS (triple quadrupole, negative ionization mode) for metrifonate and dichlorvos concentrations to confirm that the target bath concentration is maintained for at least 60 minutes. A second immersion at 7–10 days is required to target newly hatched oncomiracidia that emerge from eggs deposited on pond liner substrates, since trichlorfon lacks ovicidal activity at these concentrations. Regulatory compliance is anchored to FAO Technical Guidelines for the Responsible Use of Veterinary Chemicals in Aquaculture, the WOAH Aquatic Animal Health Code Chapter 6.11, and jurisdiction-specific maximum residue limits. Published MRL data for trichlorfon in finfish muscle indicate that residue depletion below the analytical limit of quantification (10 µg/kg by LC-MS/MS) requires a withdrawal period of 7–14 days at water temperatures above 20°C; no Codex Alimentarius numeric MRL for trichlorfon in fish has been established to date. Terminal products used by aquaculture producers include 50 g, 100 g, and 500 g water-soluble powder sachets, 5 L and 20 L HDPE jerrycan stock solutions at 10% w/v, and 1 g effervescent tablets for small tank treatment of koi carp and ornamental goldfish.Wet granulation of purified metrifonate for oral tablet manufacture in cattle and sheep requires strict moisture control because the API is highly hygroscopic and undergoes hydrolytic degradation above 45°C or at relative humidity above 40% during processing. The granulation step is performed in a high-shear granulator (e.g., GEA Aeromatic-Fielder PMA 25 L bowl) with a 5–10% w/v aqueous binder solution of povidone K30 and crospovidone 2–5% w/w as disintegrant, sprayed at a rate of 20–35 g/min until the wet mass reaches a torque value of 18–22 N·m on the impeller shaft. Batch-to-batch variation in raw API particle size distribution—typically D90 below 75 µm for content uniformity compliance—must be monitored by laser diffraction (dry dispersion at 2 bar) because particles above 150 µm cause segregation during hopper discharge and result in tablet content uniformity failures under Ph.Eur. 2.9.40 acceptance value criteria. The wet granulate is dried in a fluidized bed dryer at inlet air temperature 40–45°C to a final moisture content of 1.5–2.0% w/w determined by Karl Fischer titration (USP 921 Method Ia). Dried granules are blended with magnesium stearate 0.5% w/w and compressed on a rotary tablet press at a main compression force of 8–15 kN using 9 mm round concave punches for 500 mg tablets.

Main compression force (kN)	Tablet crushing strength (kP)	Disintegration time (min)	Dissolution at 30 min (% of label)
8	5–7	3–5	87–94
12	8–11	8–12	82–89
15	12–15	15–20	76–83

The prescribed oral dose for cattle and sheep is 50–75 mg/kg body weight administered as a single dose, based on target animal safety data referenced in VICH GL42. Tablet strengths of 250 mg, 500 mg, and 1 g accommodate animal size categories; dissolution testing per Ph.Eur. 2.9.3 using 900 mL of pH 6.8 phosphate buffer at 37°C with paddle apparatus at 50 RPM requires release of not less than 80% of labelled trichlorfon within 30 minutes. Film coating with hydroxypropyl methylcellulose (6–8 cP viscosity grade) is applied at 2–3% w/w weight gain in a side-vented coating pan to reduce moisture uptake during storage. The finished product is packaged in aluminium/PVC blister strips with desiccant sachets to maintain moisture levels below 0.5 g H₂O/kg at storage conditions of 25°C/60% RH per VICH GL3 stability requirements. Terminal products for this segment include oral tablets, oral drench solutions of 10–20% w/v trichlorfon in propylene glycol/water co-solvent, and oral powders for reconstitution in drinking water.

Carrier hardness and moisture content dictate premix shelf-life in weaner feed batches

At the receiving dock of a medicated feed mill, carrier material selection for trichlorfon premix is governed by three physical parameters: bulk density within 0.55–0.85 g/cm³, moisture content below 1.5% w/w, and sieve retention of less than 5% on a 250 µm mesh to ensure free-flowing dispersibility. Calcium carbonate (38 µm median particle size) and ground rice hulls (425 µm) are the two most commonly evaluated carriers, but published stability data indicate that calcium carbonate at pH 9–10 accelerates trichlorfon hydrolysis to dichlorvos during storage more rapidly than rice hulls at pH 6.5–7.0. For this reason, premix manufacturers specify rice hulls or acid-washed kaolin as the sole permitted carriers for trichlorfon premix concentrates at 5–10% w/w active ingredient. Geometric dilution is performed in a double-ribbon blender (500–2000 kg capacity) with mixing time of 10–15 minutes at ribbon shaft speed 60–80 RPM; blend uniformity is validated by HPLC quantitation of trichlorfon in 10 stratified sampling locations, with acceptance criteria set at relative standard deviation not exceeding 5% per FDA Guidance for Industry on Powder Blends and Finished Dosage Units (2003). Batch-to-batch potency variance in the API itself—typically not exceeding ±2% of label claim for the 97.0% minimum assay material—must be documented in the certificate of analysis and compensated for during premix weigh-up to maintain final feed concentration within ±0.005% of the prescribed dosage.The medicated complete feed is prepared by incorporating the 5–10% w/w premix at a rate of 0.5–1.0 kg per metric ton of finished feed, yielding a final trichlorfon concentration of 0.05–0.1% (equivalent to 500–1000 ppm) for the treatment of Ascaris suum and Oesophagostomum dentatum in growing pigs. Pelletizing follows incorporation using a ring-die pellet mill with die compression ratio of 1:8 and die temperature maintained below 70°C to limit thermal degradation; post-pellet moisture must be returned to 12% or below by counter-flow cooling before bagging to prevent in-bag hydrolysis. Compliance standards for this segment include FDA 21 CFR 558 (Medicated Feed Mill Licensing), FDA 21 CFR 225 (Current Good Manufacturing Practice for Medicated Feeds), ISO 6497:2013 (Animal Feeding Stuffs — Sampling), and VICH GL11 (residue studies in target animal species). Terminal products manufactured downstream include 5 kg and 25 kg multilayer paper/PE-lined premix bags, 25 kg medicated feed granules, and 1 kg oral powder for in-feed mixing at farm level.The aqueous hydrolytic degradation of metrifonate at pH above 7.0 imposes a strict 24-hour discard window on prepared drinking water solutions used for control of Ascaridia galli and Heterakis gallinarum in replacement pullets and broiler breeders. The API is supplied as a water-soluble powder with a minimum solubility of 12% w/v at 25°C in purified water; for farm-level use, the powder is dissolved to a 1–2% w/v stock solution in cold water (15–25°C) with continuous stirring using a low-shear impeller at 100–150 RPM for 5–10 minutes. The freshly prepared stock solution is buffered to pH 5.5–6.0 with citric acid/0.02 M sodium citrate to suppress hydrolytic conversion to dichlorvos, then filtered through an 80-mesh stainless steel inline strainer to remove insoluble excipients before entering the water line. Dosing is accomplished with a proportional injector calibrated at 1:100 dilution setting to deliver an average daily dose of 40–60 mg trichlorfon per kg body weight over 4–6 hours of the drinking day. Hard water with calcium ion concentration above 100 mg/L has been observed on production sites to reduce dissolution rate and form visible precipitate films on water nipple assemblies; in such cases, 0.1% w/w EDTA disodium salt is co-dissolved as a chelating agent to maintain solution clarity and prevent clogging in bell drinkers.The manufacturing process for the water-soluble powder itself involves dry blending of API with dextrose monohydrate and citric acid at a ratio of 1:9 in a V-blender (100 L capacity, 15 minutes at 25 RPM) followed by packaging into moisture-barrier foil laminate sachets of 10 g, 25 g, and 50 g. Each sachet is labelled with the batch assay value determined by HPLC-DAD at 210 nm per USP 621, and batch release requires content uniformity testing per Ph.Eur. 2.9.40 with acceptance value not exceeding 15.0. Compliance standards referenced for this segment include EU Regulation (EC) No 470/2009 for residue evaluation of pharmacologically active substances, the Ph.Eur. Trichlorfon monograph, VICH GL3 (stability of new veterinary drug substances), and VICH GL18 (residual solvents). Terminal products include water-soluble powder sachets, 1 L and 5 L concentrated oral solution (10% w/v) for proportioner dilution, and 100 g oral powder for manual dosing in small flocks.Published data for the specific configuration of trichlorfon as a canine oral capsule for demodicosis is limited, and this application was substantially replaced by topical amitraz and oral isoxazoline therapy following the European Medicines Agency referral of 2004 that raised cholinesterase inhibition safety concerns in companion animals. Where the historical formulation remains on the market, the compounding procedure involves dry blending of 97.0–100% trichlorfon powder with lactose monohydrate (80 mesh grade) and 0.5% magnesium stearate in a cube blender for 10 minutes, then encapsulation into hard gelatin capsules of 100 mg and 250 mg strengths using a semi-automatic capsule filling machine. The dose administered in veterinary dermatology practice was 25–50 mg/kg body weight per day, divided into 2 equal daily doses for 14–21 days, with the lower end of the dose range restricted to dogs weighing less than 10 kg. Clinical response correlated with reduction in Demodex canis mite counts on deep skin scrapings, but adverse cholinergic effects—salivation, lacrimation, urination, defecation, and miosis—were observed at total daily doses above 60 mg/kg, and the drug was contraindicated in dogs with concurrent Dirofilaria immitis microfilaraemia due to additive cholinergic burden. Published safety data for long-term use is limited. Compliance references for this segment include FDA 21 CFR 514 (New Animal Drug Applications), EU Regulation 2019/6 Article 106 (examination of products with withdrawn authorizations), and VICH GL42 (target animal safety). Terminal products consist of hard gelatin capsules in 100 mg and 250 mg strengths packed in 10-capsule aluminium/PVC blisters.

Ovine Oral Drench Rheology and pH-Dependent Hydrolysis Stabilisation

The oral drench formulation of metrifonate for sheep presents a shear-thinning rheology requirement that is resolved through a co-solvent matrix of propylene glycol (60–70% v/v) and deionized water (30–40% v/v) containing 10–20% w/v trichlorfon. The formulation pH is adjusted to 5.5–6.0 with citric acid monohydrate (0.5–1.0% w/w) to suppress hydrolytic conversion to dichlorvos during the 24-month shelf-life claimed under VICH GL3 long-term stability conditions of 25°C/60% RH. The drench is manufactured by adding the API to the propylene glycol phase at 15–20°C with high-shear stirring (Ross HSM-100 at 1500 RPM), followed by slow addition of the aqueous buffer phase under vacuum to prevent air entrapment; the resulting solution has a viscosity of 45–85 mPa·s at 20°C measured by Brookfield rotational viscometer (spindle LV 2, 60 RPM). The single oral dose for sheep is 75 mg/kg body weight, targeting late-stage immature and adult Fasciola hepatica as well as Oestrus ovis nasal bot larvae. Peak plasma trichlorfon concentration after oral dosing is reached at 2–4 hours, and plasma acetylcholinesterase inhibition is measurable at 6 hours post-dose, returning to 80% of baseline by 24 hours and to baseline by 72 hours. Withholding periods for meat and milk are established at 28 days and 72 hours respectively in jurisdictions where trichlorfon remains authorized for food-producing animals, based on residue depletion studies submitted under VICH GL49. Compliance standards for the drench segment include Ph.Eur. 2.9.6 (uniformity of mass of single-dose preparations), Ph.Eur. 2.9.3 (dissolution), ISO 9001:2015 for quality management in manufacturing, and Good Manufacturing Practice per EU EudraLex Volume 4 Part 2 for veterinary medicinal products. Terminal products include 100 mL, 250 mL, and 1 L oral drench bottles with dosing gun calibrations of 1 mL gradation, 10% w/w oral paste in dial-a-dose syringes, and 50 g oral powder for reconstitution by farm personnel.